Cited by 1,598Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Open access

Bean, James, Brennan, Cameron, Shih, Jin-Yuan, Riely, Gregory, Viale, Agnes, Wang, Lu, Chitale, Dhananjay, Motoi, Noriko, Szoke, Janos, Broderick, Stephen, Balak, Marissa, Chang, Wen-Cheng, Yu, Chong-Jen, Gazdar, Adi, Pass, Harvey, Rusch, Valerie, Gerald, William, Huang, Shiu-Feng, Yang, Pan-Chyr, Miller, Vincent, Ladanyi, Marc, Yang, Chih-Hsin, Pao, William·2007·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0710370104PMC PMC2409244

Open this paper in CoChat — free account

Abstract

In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib. To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance. Among three loci demonstrating recurrent copy number alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene. Collectively, analysis of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test). Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFR(T790M) mutation. We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addition to a drug-sensitive EGFR mutation and the T790M change. Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET. Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.

Integrity signals

Registry

Crossref · 10.1073/pnas.0710370104

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Circular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,304
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Show all 37 references

Research works printed but not linked: 1

BA Weir, MS Woo, G Getz, S Perner, L. Ding, R Beroukhim, WM Lin, MA Province, A Kraja, L Johnson, et al. Nature, 10.1038. (2007).

Sorted by citations

Items 601–700 of 1,001

Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance
Jotte, R. M., & Spigel, D. R. (2015) · Cancer Medicine · doi:10.1002/cam4.506 · Cited by 51
DARPP-32 Increases Interactions Between Epidermal Growth Factor Receptor and ERBB3 to Promote Tumor Resistance to Gefitinib
Zhu, S., Belkhiri, A., & El-Rifai, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.070 · Cited by 44
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Wang, M., Padhye, S., Guin, S., Ma, Q., & Zhou, Y.-Q. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.106 · Cited by 47
Somatic mutations of signaling genes in non-small-cell lung cancer
Sanders, H. R., & Albitar, M. X. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.07.134 · Cited by 50
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., Sukoh, N., Harada, M., Maemondo, M., Saijo, Y., et al. (2010) · Oncology · doi:10.1159/000326488 · Cited by 46
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs
Nakata, A., Yoshida, R., Yamaguchi, R., Yamauchi, M., Tamada, Y., Fujita, A., Shimamura, T., Imoto, S., Higuchi, T., Nomura, M., et al. (2015) · Scientific Reports · doi:10.1038/srep13076 · Cited by 47
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
Suda, K., & Mitsudomi, T. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1524-7 · Cited by 47
Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.009 · Cited by 48
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
Wang, Y., Tian, P., Xia, L., Li, L., Han, R., Zhu, M., Lizaso, A., Tian, Q., Li, M., Yu, B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.003 · Cited by 48
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48
Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Pan, Q., Lu, Y., Li, X., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00792 · Cited by 48
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
Patnaik, A., Weiss, G. J., Papadopoulos, K., Hofmeister, C. C., Tibes, R., Tolcher, A. W., Isaacs, R., Jac, J., Han, M., Payumo, F. C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.290 · Cited by 46
JAK 2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation
Harada, D., Takigawa, N., Ochi, N., Ninomiya, T., Yasugi, M., Kubo, T., Takeda, H., Ichihara, E., Ohashi, K., Takata, S., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02363.x · Cited by 46
Effector mechanisms of therapeutic antibodies against ErbB receptors
Peipp, M., Dechant, M., & Valerius, T. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.012 · Cited by 48
Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer
Wenze, S., Liping, S., Ai, T., Yingbing, Z., Ying, G., & Cui, J. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130004 · Cited by 46
Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer
Pietanza, M. C., Gadgeel, S. M., Dowlati, A., Lynch, T. J., Salgia, R., Rowland, K. M., Wertheim, M. S., Price, K. A. R., Riely, G. J., Azzoli, C. G., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824c943f · Cited by 46
Self-citation
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
Hossam, M., Lasheen, D. S., & Abouzid, K. A. M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600063 · Cited by 45
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Ninomiya, K., Ohashi, K., Makimoto, G., Tomida, S., Higo, H., Kayatani, H., Ninomiya, T., Kubo, T., Ichihara, E., Hotta, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20326-z · Cited by 45
Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology
Bing, Z., Cheng, Z., Shi, D., Liu, X., Tian, J., Yao, X., Zhang, J., Wang, Y., & Yang, K. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2347-x · Cited by 45
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Reckamp, K. L., Frankel, P. H., Ruel, N. H., Mack, P. C., Gitlitz, B. J., Li, T., Koczywas, M., Gadgeel, S. M., Cristea, M. C., Belani, C. P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00132 · Cited by 46
Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors
Javadi, S., Zhiani, M., Mousavi, M. A., & Fathi, M. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151083 · Cited by 44
Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
Fei, S.-J., Zhang, X., Dong, S., Cheng, H., Yi-fang, Z., Huang, L., Zhou, H., Xie, Z., Chen, Z., & Wu, Y.-L. L. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069104 · Cited by 45
Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
Fong, J., Jacobs, R. J., Moravec, D. N., Uppada, S. B., Botting, G. M., Nlend, M., & Puri, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078398 · Cited by 45
Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Zhong, H. A., & Bowen, J. P. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860924 · Cited by 45
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma
Mataki, H., Seki, N., Chiyomaru, T., Enokida, H., Goto, Y., Kumamoto, T., Machida, K., Mizuno, K., Nakagawa, M., & Inoue, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2802 · Cited by 45
Biomarker development in MET-targeted therapy
Zhang, Y., Du, Z., & Zhang, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8276 · Cited by 45
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Botting, G. M., Rastogi, I., Chhabra, G., Nlend, M., & Puri, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136155 · Cited by 46
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
Lee, S., & McLeod, H. L. (2010) · The Journal of Pathology · doi:10.1002/path.2766 · Cited by 44
Molecular testing in lung cancer in the era of precision medicine.
Popper, H., Ryška, A., Tı́már, J., & Olszewski, W. T. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.10.01 · Cited by 44
Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors
Bertotti, A., Bracco, C., Girolami, F., Torti, D., Gastaldi, S., Galimi, F., Medico, E., Elvin, P., Comoglio, P., & Trusolino, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0106 · Cited by 47
Targeting the HGF/c-Met Axis: State of Play
Yap, T. A., & Bono, J. S. D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0122 · Cited by 44
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Sesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Burtness, B. A., & Faller, B. A. (2009) · Biologics · doi:10.2147/btt.2009.3546 · Cited by 44
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value
Chai, X., Yinwang, E., Wang, Z., Wang, Z., Xue, Y., Li, B., Zhou, H., Zhang, W., Wang, S., Zhang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692788 · Cited by 43
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer
Lai, A. Z., Cory, S. M., Zhao, H., Gigoux, M., Monast, A., Guiot, M.-C., Huang, S., Tofigh, A., Thompson, C., Naujokas, M. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004839 · Cited by 44
Self-citation
Erlotinib
Petit-Jean, E., Buclin, T., Guidi, M., Quoix, É., Gourieux, B., Decosterd, L. A., Gairard-Dory, A., Ubeaud-Séquier, G., & Widmer, N. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000097 · Cited by 43
Identification of novel N-(2-aryl-1, 3-thiazolidin-4-one)-N-aryl ureas showing potent multi-tyrosine kinase inhibitory activities
Qi, B., Yang, Y., He, H., Yue, X., Zhou, Y., Zhou, X., Chen, Y., Liu, M., Zhang, A., & Wei, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.061 · Cited by 43
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
Wang, S., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198945 · Cited by 42
c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy
Mohan, C. D., Shanmugam, M. K., Gowda, S. G. S., Chinnathambi, A., Rangappa, K. S., & Sethi, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155379 · Cited by 42
PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
Wu, D., Wu, T., Chen, C., & Lee, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2724 · Cited by 42
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion
Subbiah, V., Holmes, O., Gowen, K. A., Spritz, D., Amini, B., Wang, W., Schrock, A. B., Meric‐Bernstam, F., Zinner, R., Piha-Paul, S. A., et al. (2016) · Oncology · doi:10.1159/000449204 · Cited by 41
Self-citation
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)—from morphology to molecular testing
Righi, L., Franzi, F., Montarolo, F., Gatti, G., Bongiovanni, M., Sessa, F., & Rosa, S. L. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.158 · Cited by 42
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer
Girard, N. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01022-7 · Cited by 40
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42
The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors
Belani, C. P. (2010) · Cancer Investigation · doi:10.3109/07357901003631072 · Cited by 41
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 42
Clinical cancer genomics: how soon is now?
Taylor, B. S., & Ladanyi, M. (2010) · The Journal of Pathology · doi:10.1002/path.2794 · Cited by 41
Self-citation
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
Lou, N.-N., Zhang, X., Chen, H., Zhou, Q. H., Yan, L., Xie, Z., Su, J., Chen, Z., Tu, H., Yan, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11218 · Cited by 43
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Tarhini, A. A., Rafique, I., Floros, T., Tran, P. N., Gooding, W. E., Villaruz, L., Burns, T. F., Friedland, D., Petro, D. P., Farooqui, M., et al. (2017) · Cancer · doi:10.1002/cncr.30717 · Cited by 42
In silico identification of potential key regulatory factors in smoking-induced lung cancer
El-aarag, S. A., Mahmoud, A., Hashem, M. H., Elkader, H. A., Hemeida, A. A., & ElHefnawi, M. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0284-z · Cited by 41
Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells
Kinehara, Y., Nagatomo, I., Koyama, S., Ito, D., Nojima, S., Kurebayashi, R., Nakanishi, Y., Suga, Y., Nishijima-Futami, Y., Osa, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.123093 · Cited by 40
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting
Schubart, C., Stöhr, R., Tögel, L., Fuchs, F. S., Sı̂rbu, H., Seitz, G., Seggewiß-Bernhardt, R., Leistner, R., Sterlacci, W., Vieth, M. W., et al. (2021) · Cancers · doi:10.3390/cancers13195023 · Cited by 41
Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
Chatziandreou, I., Tsioli, P., Sakellariou, S., Mourkioti, I., Giannopoulou, I., Levidou, G., Korkolopoulou, P. A., Patsouris, E., & Saetta, A. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133859 · Cited by 43
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Ghosh, G., Lian, X. L., Kron, S. J., & Palecek, S. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-95 · Cited by 39
A growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 40
Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line
Faehling, M., Eckert, R., Kuom, S., Kamp, T., Stoiber, K., & Schumann, C. (2010) · Oncology · doi:10.1159/000315731 · Cited by 40
Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
Li, H., Hu, H., Wang, R., Pan, Y., Wang, L., Li, Y., Zhang, Y., Ye, T., Zhang, Y., Li, B., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60122 · Cited by 40
Self-citation
The Potential of panHER Inhibition in Cancer
Wang, X., Batty, K., Crowe, P. J., Goldstein, D., & Yang, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00002 · Cited by 40
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
Noto, A., Vitis, C. D., Roscilli, G., Fattore, L., Malpicci, D., Marra, E., Luberto, L., D’Andrilli, A., Coluccia, P., Giovagnoli, M. R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1141 · Cited by 41
Imaging of Lung Cancer in the Era of Molecular Medicine
Nishino, M., Jackman, D. M., Hatabu, H., Janne, P. A., Johnson, B. E., & den Abbeele, A. D. V. (2011) · Academic Radiology · doi:10.1016/j.acra.2010.10.020 · Cited by 40
Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells
Ko, J., Hong, J.-H., Wang, L.-H., Cheng, C.-M., Ciou, S., Lin, S., Jheng, M.-Y., & Lin, Y. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0578 · Cited by 40
Self-citation
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer
Chmielecki, J., Peifer, M., Jia, P., Socci, N. D., Hutchinson, K. E., Viale, A. J., Zhao, Z., Thomas, R. K., & Pao, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq579 · Cited by 40
Self-citation
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer
Lara, M. S., Holland, W. S., Chinn, D. C., Burich, R. A., Lara, P. N., Gandara, D. R., Kelly, K. L., & Mack, P. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.006 · Cited by 40
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression
Socinski, M. A., Villaruz, L. C., & Ross, J. S. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0285 · Cited by 40
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
Angevin, E., Spitaleri, G., Rodon, J. A., Dotti, K. F., Isambert, N., Salvagni, S., Moreno, V., Assadourian, S., Gomez, C., Harnois, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.016 · Cited by 40
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Ai, J., Chen, Y., Xia, P., Ji, Y., Xi, Y., Shen, Y., Yang, X., Su, Y., Sun, Y., Gao, Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0368 · Cited by 40
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
Casaletto, J. B., Geddie, M. L., Abu‐Yousif, A. O., Masson, K., Fulgham, A., Boudot, A. J., Maiwald, T., Kearns, J. D., Kohli, N., Su, S. V., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819085116 · Cited by 40
Non-small cell lung cancer - genetic predictors
Koudeláková, V., Kneblova, M., Trojanec, R., Drábek, J., & Hajdúch, M. (2013) · Biomedical Papers · doi:10.5507/bp.2013.034 · Cited by 39
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
Luo, M., & Fu, L.-W. (2014) · Europe PMC (PubMed Central) · Cited by 38
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
Steen, N. V. D., Pauwels, P., Bazo, I. G., Álvarez, E. C., Raez, L. E., Cappuzzo, F., & Rolfo, C. D. (2015) · Cancers · doi:10.3390/cancers7020556 · Cited by 39
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma
Olanich, M. E., & Barr, F. G. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772136 · Cited by 39
Targeted Inhibition of Kinases in Cancer Therapy
Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 39
Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations
Wang, Z., Shen, Z., Li, Z., Duan, J., Fu, S., Liu, Z., Bai, H., Zhang, Z., Zhao, J., Wang, X., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510837112 · Cited by 39
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
Wu, D.-W., Chen, T.-C., Huang, H., & Lee, H. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.192 · Cited by 39
The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).
Xu, M. M., Xie, Y., Ni, S., & Liu, H. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.60 · Cited by 41
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors
Xin, Y., Jin, D., Eppler, S., Damico‐Beyer, L. A., Joshi, A., Davis, J. D., Kaur, S., Nijem, I., Bothos, J. G., Peterson, A., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.148 · Cited by 39
Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells
Yamauchi, Y., Izumi, Y., Yamamoto, J., & Nomori, H. (2013) · Phytotherapy Research · doi:10.1002/ptr.5056 · Cited by 39
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Liang, J., Bi, G., Sui, Q., Zhao, G., Zhang, H., Bian, Y., Chen, Z., Huang, Y., Xi, J., Shi, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113771 · Cited by 38
Molecular Diagnostics of Lung Carcinomas
Đačić, S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0625-rair.1 · Cited by 38
Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
Machida, K., Eschrich, S. A., Li, J., Bai, Y., Koomen, J. M., Mayer, B. J., & Haura, E. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013470 · Cited by 38
Targeting the oncogenic Met receptor by antibodies and gene therapy
Vigna, E., & Comoglio, P. M. (2014) · Oncogene · doi:10.1038/onc.2014.142 · Cited by 38
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
Yoshida, T., Ishii, G., Goto, K., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., Nagai, K., Ohe, Y., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1495-0 · Cited by 38
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Cadranel, J. L., Zalcman, G., & Sequist, L. V. D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00179409 · Cited by 39
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Mancini, M., Gaborit, N., Lindzen, M., Salame, T. M., Dall’Ora, M., Sevilla-Sharon, M., Abdul‐Hai, A., Downward, J., & Yarden, Y. (2015) · Science Signaling · doi:10.1126/scisignal.aaa0725 · Cited by 38
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
Cappuzzo, F., Morabito, A., Normanno, N., Bidoli, P., Conte, A. D., Giannetta, L. G., Montanino, A., Mazzoni, F., Buosi, R., Burgio, M. A., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.008 · Cited by 39
Development of bispecific antibodies in China: overview and prospects
Zhang, J., Yi, J., & Zhou, P. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa011 · Cited by 38
Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer
Hassanabad, A. F., & MacQueen, K. T. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00570-0 · Cited by 40
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors
Krause, M., Gurtner, K., Deuse, Y., & Baumann, M. A. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232835 · Cited by 38

Authors: Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., Balak, M., Chang, W.-C., Yu, C.-J., Gazdar, A., Pass, H., Rusch, V., Gerald, W., Huang, S.-F., Yang, P.-C., Miller, V., Ladanyi, M., Yang, C.-H., & Pao, W.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
National Taiwan University (TW)
Department of Pathology, Memorial Sloan–Kettering Cancer Center, New York, NY 10021;
Chang Gung Memorial Hospital (TW)
The University of Texas Southwestern Medical Center (US)
NYU Langone Health (US)
National Health Research Institutes (TW)
National Taiwan University Hospital (TW)
ORCID: Bean, James
Brennan, Cameron
Shih, Jin-Yuan
Riely, Gregory
Viale, Agnes
Wang, Lu
Chitale, Dhananjay
Motoi, Noriko
Broderick, Stephen
Yu, Chong-Jen
Gazdar, Adi
Pass, Harvey
Rusch, Valerie
Huang, Shiu-Feng
Yang, Pan-Chyr
Miller, Vincent
Ladanyi, Marc
Pao, William
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2007-12-26
Volume: 104
Issue: 52
Pages: 20932-20937
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0710370104
PMC: PMC2409244
OpenAlex: W2093613683
Cited by: 1,598
References: 37
Citations by year: 2026: 17 · 2025: 19 · 2024: 33 · 2023: 42 · 2022: 59 · 2021: 54 · 2020: 78 · 2019: 78 · 2018: 100 · 2017: 89 · 2016: 116 · 2015: 135 · 2014: 124 · 2013: 148 · 2012: 126
FWCI: 71.72
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Conquer Cancer Foundation
Memorial Sloan-Kettering Cancer Center
Exelixis
National Cancer Institute (U01 CA 84999, P50CA75907, R01CA121210, U01CA084999, K08CA097980, R21CA115051)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, T790M mutation, EGFR mutation, lung adenocarcinoma, acquired drug resistance, gefitinib, erlotinib, EGFR tyrosine kinase inhibitors, copy number alterations, multikinase inhibitor, therapeutic target
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Proto-Oncogene Mas, Adenocarcinoma, Antineoplastic Agents, Chromosomes, Human, Pair 7, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Quinazolines, Cohort Studies, Gene Expression Regulation, Neoplastic, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks